Current CD4 Count, More than Baseline, Predicts Loss to Follow-up from HIV Care

Similar documents
Costs of inpatient treatment for multi-drug resistant tuberculosis in South Africa

The Basics of Drug Resistance:

Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH

Antiretroviral therapy for HIV infection in infants and children: Towards universal access

Authors: Matthew Fox *, Prudence Ive, Lawrence Long, Mhairi Maskew, Ian Sanne

TUBERCULOSIS (TB) TREATMENT OUTCOMES IN ADULT TB PATIENTS ATTENDING A RURAL HIV CLINIC IN SOUTH AFRICA (Bushbuckridge).

Seroprevalence and risk factors of Lassa fever infection in Nasarawa State, Nigeria 2013

Chapter 3 South African guidelines and introduction to clinical cases

Six-Month Outcomes from a Medical Care Coordination Program at Safety Net HIV Clinics in Los Angeles County (LAC)

Earlier, safer and simpler antiretroviral therapy can push the HIV epidemic into irreversible decline. -WHO Director-General Dr.

Acute HCV was defined as (3 out of 4 within the preceding 4 months):

Generic antiretrovirals in Europe: a blessing or a curse?

STOP HIV/AIDS Quarterly Monitoring Report

Outcomes of Antiretroviral Treatment Programs in Rural Southern Africa

STOP HIV/AIDS Quarterly Monitoring Report


Frequently Asked Questions (FAQs)

The VEdeTTE cohort study: Effectiveness of treatments for heroin addiction in retaining patients and reducing mortality

Routine HIV Monitoring

Nelfinavir: Where are we now? Experience in Ghana

Refugees with diabetes mellitus have higher prevalence of latent tuberculosis infection

Management of HIV and TB Co-infection in South Africa

In Tanzania, ARVs were introduced free-of-charge by the government in 2004 and, by July 2008, almost 170,000 people were receiving the drugs.

HBV screening and management in HIV-infected children and adolescents

Module 4: Formulating M&E Questions and Indicators

Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver

THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2013

Measures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University

The Botswana Combination Prevention Project (BCPP)

Prescription Opioid Use and Opioid-Related Overdose Death TN,

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA

SAS and R calculations for cause specific hazard ratios in a competing risks analysis with time dependent covariates

HIV Epidemiology in New York State

Homeopathy as a treatment for HIV and Aids in Swaziland

Estimated GFR Based on Creatinine and Cystatin C

INTEGRATED CLINICAL SYSTEMS MANAGEMENT QUALITY IMPROVEMENT OF CARE OF PLWHA

Population, Health, and Human Well-Being-- Benin

Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa

How Can We Get the Best Medication History?

TRENDS IN CIGARETTE SMOKING AND THE RELATIONSHIP WITH FAILING TO BE RETAINED IN HIV PRIMARY CARE, by Amanda Lee Johnson

Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total

Statistical release P0302

Impact of Diabetes on Treatment Outcomes among Maryland Tuberculosis Cases, Tania Tang PHASE Symposium May 12, 2007

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD

EACS Dominique Braun Universitätsspital Zürich

Coun%ng sick children: es%ma%ng the global incidence of childhood tuberculosis

Potential impact of routine testing of patients with HIV indicator disease in preventing late HIV diagnosis

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents

Cost and outcomes of paediatric antiretroviral treatment in South Africa

!400 copies/ml [12, 13]. Continuous viral suppression

Outcomes of the Botswana national HIV/AIDS treatment programme from 2002 to 2010: a longitudinal analysis

Page 1/.. USA / Canada - South Africa Schedule No. 4 / 2011-Jan-24

FARMACI, INNOVAZIONE e INFEZIONE DA HIV / AIDS

Elevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality

Prognostic impact of uric acid in patients with stable coronary artery disease

Table e-1: Description of the three participating centres Umeå, Sweden Dublin, Ireland Barcelona, Spain Population-based study with single

Response to HIV/AIDS in Brazil, public health system strengthening and programmatic integration

Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014

HEALTH SPECIALIST VISITS (HSV) PROGRAMME. All Cook Islanders living healthier lives and achieving their aspirations

INSTITUTE AND FACULTY OF ACTUARIES EXAMINATION

HCV Case Study. Optimizing Outcomes with Current Therapies

Treatment Information Service HIV 0440 HIV/AIDS. HIV and Its Treatment What You Should Know. 2nd edition

A LONGITUDINAL AND SURVIVAL MODEL WITH HEALTH CARE USAGE FOR INSURED ELDERLY. Workshop

Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH)

Big Data Health Big Health Improvements? Dr Kerry Bailey MBBS BSc MSc MRCGP FFPH Dr Kelly Nock MPhys PhD

HIV Therapy Key Clinical Indicator (KCI)

Supplementary Online Content

London Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL

Poster # 42 Resistance in PBMCs Can Predict Virological Rebound after Therapy Switch in cart- Treated Patients with Undetectable HIV-RNA

hiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting

Tips for surviving the analysis of survival data. Philip Twumasi-Ankrah, PhD

Presented By: Amy Medley PhD, MPH Centers for Disease Control and Prevention

Monitoring and Evaluation Framework

Correlates of not receiving HIV care among HIV-infected women enrolling in a HRSA SPNS multi-site initiative

AN OVERVIEW OF PROGRAMS FOR PEOPLE WHO INJECT DRUGS

People living. Since the start of the AIDS epidemic, more than 78 million people have been infected with HIV and 39 million have died (1).

Funding UK Medical Research Council, Development Cooperation Ireland, and Canadian International Development

Service Availability and Readiness Assessment (SARA)

Abstract. PLOS Medicine 1 July 2014 Volume 11 Issue 7 e

An Investigation of Classification Algorithms for Predicting HIV Drug Resistance without Genotype Resistance Testing

The studies reported in this thesis were performed at the department of Viroscience of the Erasmus Medical Center, Rotterdam, the Netherlands.

How does the NHS buy HIV Drugs?

Big data size isn t enough! Irene Petersen, PhD Primary Care & Population Health

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep)

Journal of Infectious Diseases Advance Access published January 26, 2015

TRACKS INFECTIOUS DISEASE EPIDEMIOLOGY

South African Health Sector: Presented to Budget committee By Dr. Olive Shisana CEO Human Sciences Research Council

Hilgaard F Visser MBChB Senior Registrar Department Orthopaedic Surgery, University of Pretoria

M I L L I O N S Figure 2.1 Number of people newly infected with HIV

Global Health Research Internship 2016 in Boston

PEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW. Elizabeth Comino Centre fo Primary Health Care and Equity 12-Aug-2015

HIV DRUG RESISTANCE EARLY WARNING INDICATORS

Pharmacoprevention. HIV-drugs for prevention. Instituut Tropische Geneeskunde, Antwerpen

Alaska Comprehensive Cancer Control Plan

HIV Guidelines. New Strategies.

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG study results presented at ASCO 2004

Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS

HEALTH TRANSITION AND ECONOMIC GROWTH IN SRI LANKA LESSONS OF THE PAST AND EMERGING ISSUES

Transcription:

Current CD4 Count, More than Baseline, Predicts Loss to Follow-up from HIV Care Kate Shearer 1, Matthew P Fox 1,2,3, Mhairi Maskew 1, Ian Sanne 1,4,5, Lawrence Long 1 1 Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa 2 Center for Global Health & Development, Boston University, Boston, MA, USA 3 Department of Epidemiology, School of Public Health, Boston University, Boston, MA, USA 4 Right to Care, Johannesburg, South Africa 5 Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Introduction As interest in test and treat strategies increases, the ability to retain patients in care, long-term, is increasingly important For such strategies to succeed, we need to be able to identify patients at high risk for dropping out of care not just at baseline, but over time Our objective was to describe the association between a patient s current CD4 count and loss to follow-up

Study Setting Themba Lethu Clinic Public sector HIV clinic with NGO support located in Johannesburg Dispensing ARVs since 2004 Seen more than 30,000 patients Over 12,000 patients currently receiving treatment

Methods Inclusion criteria: ART naïve adult patients ( 18 years old) Initiated between April 1, 2004 - December 31, 2011 Initiation a standard first-line regimen: Stavudine, zidovudine, or tenofovir with either lamivudine or emtricitabine and either nevirapine or efavirenz Exclusion criteria: Received previous outpatient treatment Never had a CD4 count taken Patients followed until they became lost to follow-up Censored at death, transfer, or close of dataset (Jan 2013)

Definitions Baseline CD4 count: 3 months prior to 7 days post ART initiation Current CD4 count: 6 (+/- 2) month intervals from ART initiation until leaving care or close of the dataset Lost to follow-up: 3 months late for a scheduled visit with no subsequent visit

CD4 Count Monitoring SA National ART Guidelines Recommendation for CD4 Monitoring 2004 Baseline then 6 monthly thereafter 2010 Baseline, month 6, 1 year, and then yearly thereafter 2013 Baseline and 1 year on ART

Statistical Methods Compared two models of LTF: Standard Cox proportional hazards model Time-varying Cox proportional hazards model Both unadjusted and adjusted Adjusted for sex, age at ART initiation, baseline WHO stage, BMI, anemia, and tuberculosis co-infection

Cox Proportional Hazards Models Time-to-event (survival) analyses Standard Cox proportional hazards model Explanatory variables do not change over time Sex, age at ART initiation, baseline clinical characteristics Time-varying Cox proportional hazards model Explanatory variable(s) changes over time CD4 count at each medical visit

Results Patient Characteristics Variable Exposure Lost to Follow-up Not Lost to Follow-up Total 4175 (24.7%) 12706 (75.3%) Sex Male 1804 (43.2%) 4701 (37.0%) Female 2371 (56.8%) 8005 (63.0%) Age Median (IQR) 35.4 (30.2 42.0) 37.1 (31.8 43.8) Baseline CD4 Count (cells/mm 3 ) Median (IQR) 90.0 (32.0 161.0) 95.0 (35.0 170.0) WHO Stage I/II 1923 (46.1%) 6384 (50.2%) III/IV 2252 (53.9%) 6322 (49.8%) BMI Median (IQR) 20.7 (18.5 23.6) 21.8 (19.2 25.1) Hb (g/dl) Median (IQR) 10.7 (9.1 12.3) 10.9 (9.4 12.4)

Results Baseline CD4 Model Unadjusted HR (95% CI) Adjusted HR (95% CI) Baseline CD4 (cells/mm 3 ) <50 1.13 (1.01, 1.25) 0.96 (0.85, 1.08) 50-99 0.97 (0.86, 1.09) 0.90 (0.79, 1.03) 100-199 1.00 (0.90, 1.11) 1.02 (0.91, 1.15) 200 Reference Reference Adjusted for sex, age at ART initiation, baseline WHO stage, BMI, anemia, and tuberculosis co-infection

Results Current CD4 Count Model Unadjusted HR (95% CI) Adjusted HR (95% CI) Current CD4 (cells/mm 3 ) <50 3.10 (2.60, 3.70) 2.72 (2.20, 3.36) 50-99 2.01 (1.66, 2.44) 1.85 (1.48, 2.33) 100-199 1.53 (1.30, 1.81) 1.57 (1.30, 1.90) 200 Reference Reference Adjusted for sex, age at ART initiation, baseline WHO stage, BMI, anemia, and tuberculosis co-infection

Conclusions While baseline CD4 count showed no association with loss to follow-up, having a low current CD4 count is strongly associated with loss Ongoing monitoring of CD4 count can help to identify patients at increased risk of dropping out of care

Acknowledgements Themba Lethu Clinic patients and staff Right to Care, Johannesburg, South Africa Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa Center for Global Health & Development, Boston University, Boston, USA This presentation was made possible by the generous support of the American people through Cooperative Agreement AID 674-A-12-00029 from the United States Agency for International Development (USAID). The contents are the responsibility of the authors and do not necessarily reflect the views of USAID or the United States Government Matthew Fox was also supported by Award Number K01AI083097 from the National Institute of Allergy and Infectious Diseases (NIAID).

Current CD4 Count Model with Restricted Cohort (April 2004 March 2009) Unadjusted HR (95% CI) Adjusted HR (95% CI) Current CD4 (cells/mm 3 ) <50 2.38 (1.83, 3.09) 2.15 (1.59, 2.92) 50-99 1.61 (1.22, 2.14) 1.49 (1.08, 2.06) 100-199 1.34 (1.05, 1.71) 1.34 (1.02, 1.77) 200 Reference Reference

Also adjusting for current viral load Unadjusted HR (95% CI) Adjusted HR (95% CI) Current CD4 (cells/mm 3 ) <50 3.10 (2.60, 3.70) 2.70 (1.85, 3.94) 50-99 2.01 (1.66, 2.44) 1.99 (1.37, 2.88) 100-199 1.53 (1.30, 1.81) 1.47 (1.13, 1.90) 200 Reference Reference